DonCorleone77 Posted - 1 day ago

$REGN $LLY $SRRK $KROS $BHVN From Bloomberg: Keeping muscle while losing fat is the next goal for obesity drugs. It looks like the race is on to develop drugs that both reduce weight and keeping muscle, even as some skeptical doctors say holding onto muscle is less important than shedding weight. Despite some doctor skepticism, preserving muscle is an alluring goal for drugmakers that missed the first generation of obesity treatments and are seeking a foothold in the fast-growing and lucrative market:

Stock_Titan Posted - 1 week ago

$KROS Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results https://www.stocktitan.net/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-first-im5k3oiq5zz1.html

FlynancialAnalyst Posted - 1 week ago

$KROS $2.06B mc $XBI name rotating up on volume last wk thru key $60 pivot 88.56% institutionally owned, and 'under the radar' with just 202 watchers on Stocktwits 💎👀👍 TrendEdge.app/asset/KROS

milkenmike Posted - 2 weeks ago

$KROS ELAB A lot of new players entering the obesity space. There’s lots of pitfalls with the current class of drugs. This is one to watch; initial clinical results are promising to add to GLP-1’s. Founders have a great track record building biotech companies. https://finance.yahoo.com/news/elevai-labs-acquires-exclusive-license-130000444.html

Capitulation_0 Posted - 2 weeks ago

$KROS rocking!

Capitulation_0 Posted - 04/30/24

$KROS $LLY

Capitulation_0 Posted - 04/29/24

$KROS BP should buy this for 4B.... better than MRK drug and now that's forecasted to do 8B? crazy... 2 years behind.

RiskVsReward Posted - 04/28/24

⭐Check out this chart guys!⭐ $KROS

nastento Posted - 04/28/24

@Capitulation_0 between $GOSS $INSM $AVTE $KROS I think there's a better and safer treatment than $MRK well see once sotatercept is on the market for a while

Capitulation_0 Posted - 04/26/24

$KROS moving back up to $70s

Capitulation_0 Posted - 04/26/24

$KROS Should take over share from sota when it gets approved.. it's simply a better drug. I think this bounces from here.

Capitulation_0 Posted - 04/26/24

$KROS Another stock disconnected from Analyst consensus

Capitulation_0 Posted - 04/26/24

$KROS I think people have the thesis wrong on this that sota approval somehow diminishes this asset.. not the case. this sell off is overdone. Bounce from here...

Capitulation_0 Posted - 04/26/24

$KROS broken down name for the past month..should curl. piper is at $105

nastento Posted - 03/27/24

@SarlaccButtplug 22.5 bill? I'll take 2-4 bill right now and be completely happy lol We still have $KROS and $AVTE seeking approval too Plus a few others that have treatment available. Very interesting play and ill keep adding. Doubled my position today

LaserCat Posted - 03/21/24

$KROS

Capitulation_0 Posted - 2 months ago

$GOSS and $KROS... nice moves.

Capitulation_0 Posted - 2 months ago

$GOSS really like the R/R here. Recent EMA accelerated approval for Sotatercept was pulled. This is incremental bullish for this stock and $KROS MC difference is eye popping between the 2. Best safety profile.

TheTradeXchange Posted - 2 months ago

$KROS - Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Stock_Titan Posted - 2 months ago

$KROS Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes https://www.stocktitan.net/news/KROS/keros-therapeutics-announces-u-s-fda-fast-track-designation-for-ker-jbub98p0eiqh.html

Thestocktraderhubzee Posted - 2 months ago

WATCHLIST MAR 14 2024 $STLD Citigroup Maintains Buy on Steel Dynamics, Raises Price Target to $160 $SBUX Citigroup Maintains Neutral on Starbucks, Lowers Price Target to $102 $TCBI Citigroup Maintains Neutral on Texas Capital Bancshares, Lowers Price Target to $64 $BPOP Citigroup Maintains Buy on Popular, Raises Price Target to $107 $KROS Truist Securities Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target

erevnon Posted - 2 months ago

Truist Securities reiterates Keros Therapeutics $KROS at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

Quantumup Posted - 2 months ago

Piper Sandler ~ Fri~ *Life Beyond GLP-1s Re: Preservation of Lean Muscle Mass=Unmet Need Lists $BHVN REGN $SRRK as Top Picks/Overweight $LLY also on list - Ph2b data for bimagrumab expected mid24 +Watch: $KROS OW) / rhhby $SKYE OW I've put info out on All of the above, except Roche

Stock_Titan Posted - 2 months ago

$KROS Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference https://www.stocktitan.net/news/KROS/keros-therapeutics-to-present-at-leerink-partners-2024-global-8ud1uksf3ad2.html

DonCorleone77 Posted - 02/28/24

$KROS Keros Therapeutics reports Q4 EPS ($1.34) , consensus ($1.37) "In 2023, Keros made continued clinical progress across our pipeline, including commencing our Phase 2 clinical trial evaluating KER-012 in patients with pulmonary arterial hypertension ("PAH") and presenting exciting data from our two ongoing Phase 2 clinical trials of KER-050, one in patients with myelodysplastic syndromes ("MDS") and one in patients with myelofibrosis," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. "We continue to build on that momentum in 2024, as highlighted by the advancement of our third clinical asset, KER-065, into a Phase 1 healthy volunteer clinical trial at the beginning of this year. We look forward to providing updates from the KER-050 and KER-012 programs in the first half of this year.Keros' cash and cash equivalents as of December 31 was $331.1M compared to $279.0 million as of December 31, 2022....

Stock_Titan Posted - 02/28/24

$KROS Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/KROS/keros-therapeutics-reports-recent-business-highlights-and-fourth-k9jbmhd69a0f.html

xbibackto70s Posted - 02/27/24

$KROS bullish chart

LaserCat Posted - 02/26/24

$KROS measured move up underway

Pika_Capital Posted - 02/23/24

$KROS something is cooking. Happy to sit tight with my average in low $50s

Quantumup Posted - 02/21/24

William Blair🏁 $KROS Outperform/$81~To date, KER-012 (P2 results expected in '25) has not shown hemoglobin increases or risk of bleeding, including@ supraphysiological doses in nonhuman primates, which will result in a superior therapy option for pulmonary arterial hypertension (PAH) pts; WB est $3.1B peak sales in PAH.